Corporate Profile

Merrion Pharmaceuticals is a publicly listed product development company focused on delivering innovation to the market by:

designing our own patented products and
partnering with other pharmaceutical companies to develop patented products.

Established in 2003, Merrion are engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion Pharmaceutical's patented drug delivery technology (GIPET®) hugely increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. As well as increasing absorption, Merrion's Technology also increases the consistency of absorption.

These new products can provide substantial benefits in enhanced drug efficacy, improved safety, toxicity and side effect profile, health economics, patient experience and quality of life.

Merrion has agreements with several pharmaceutical companies. Merrion has two license agreements with Novo Nordisk A/S to develop and commercialise oral forms of Novo Nordisk's Insulin and GLP-1 using Merrion's proprietary GIPET technology. Merrion also has an oral drug delivery research collaborative program with Ferring Pharmaceuticals, an undisclosed 'top ten' pharma company, Rebel Pharmaceuticals and other non disclosed pharma companies.

Merrion Pharmaceuticals is based in Dublin, in a state of the art, purpose built cGMP facility which allows rapid development and reduced risk in taking product ideas from conception to final product formulation. Merrion also has operations in Wilmington, North Carolina.

Merrion is listed on the Irish Stock Exchange (ESM) under the symbol MERR.